{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-23-000008","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.391508+00:00","generated_at":"2026-06-20T17:35:48.670572+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AtriCure reports Q4 2022 preliminary revenue $88M (+20% YoY); guides 2023 rev $380-387M","bullets":["Q4 2022 revenue ~$88M (U.S. $73.9M, intl $14.1M), up 20% YoY.","FY2022 revenue $330.4M, up 20% YoY; adjusted EBITDA loss ~$4M.","Adjusted loss per share for FY2022 estimated at $1.10–$1.12.","2023 guidance: revenue $380–$387M, growth 15–17%; EBITDA breakeven.","CEO cites strong demand across product lines; outlook reflects continued momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-23-000008","json":"https://secwatch.observer/filing/0001323885-23-000008.json","markdown":"https://secwatch.observer/filing/0001323885-23-000008.md","text":"https://secwatch.observer/filing/0001323885-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/0001323885-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/atrc-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:35:48.670572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"685d5e87b06791e77b14a91becab06cb9c544314","claim":"AtriCure, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $330.4 million, EPS approximately $1.10 to $1.12. Guidance initiated.","evidence_excerpt":"Preliminary, unaudited revenue for fourth quarter 2022 is expected to be approximately $88.0 million, reflecting growth of approximately 20% over the fourth quarter of 2021 (21% on a constant currency basis).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/0001323885-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$330.4 million"},{"label":"EPS","value":"approximately $1.10 to $1.12"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"685d5e87b06791e77b14a91becab06cb9c544314","claim":"AtriCure, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $330.4 million, EPS approximately $1.10 to $1.12. Guidance initiated.","evidence_excerpt":"Preliminary, unaudited revenue for full year 2022 is expected to be $330.4 million, reflecting growth of approximately 20% over full year 2021 (22% on a constant currency basis).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/0001323885-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$330.4 million"},{"label":"EPS","value":"approximately $1.10 to $1.12"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}